Xoma (US)
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Xoma (US) sits in the top decile of US sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count).
Xoma (US): 20 sponsored US clinical trials, none currently recruiting.
Xoma (US) sponsors 20 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 12 completed. 7 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acne Vulgaris, with 1 trials.
Top-decile sponsor footprint
Xoma (US) ranks in the top decile of sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
12 of 20 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (60.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
20 total, page 1 of 1
An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery
NCT02772718
A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism
NCT02604485
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
NCT02326740
Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
NCT02258867
A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
NCT02318914
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
NCT02315417
An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data
NCT02258854
The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease
NCT01950312
Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum
NCT01882504
Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand
NCT01882491
Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the Hand
NCT02293564
Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment
NCT01747538
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
NCT01684345
Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand
NCT01683396
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
NCT01498874
Safety and Efficacy of XOMA 052 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin Monotherapy
NCT01066715
Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Type 2 Diabetes Mellitus
NCT00513214
Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
NCT00454155
Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas
NCT00051675
Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.
NCT00034203
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 9 |
| Phase 3 | 7 |
Therapeutic Areas
How the Xoma (US) early-phase archive is shaped
20 indexed studies, none listed as recruiting (0% open); 12 completed (60%).
Phase mix: 7 late (III/IV) vs 12 early (I/II) (early-phase heavy).
Top condition: Acne Vulgaris (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Xoma (US): archived-pipeline peers nationwide
Peers matched on 20 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Xoma (US) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 20 archived trials
- 59th Medical Wing · 20 trials · 15% recruiting
- Abiomed · 20 trials · 10% recruiting
- Agency for Healthcare Research and Quality (AHRQ) · 20 trials · 0% recruiting
- Alliance Foundation Trials · 20 trials · 15% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Xoma (US) page
20 registered trials is a research-attention snapshot, not an endorsement of Xoma (US) or any single study.
- None of Xoma (US)'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Acne Vulgaris is the condition Xoma (US) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acne Vulgaris trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Xoma (US) pipeline card: 20 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.